|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 55511th STREET, NW |
Address2 | Suite #300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 288670-12
|
||||||||
|
6. House ID# 371000000
|
TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Anita Drummond |
Date | 10/22/2018 3:35:30 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Federal budget and appropriations for cancer research and programs, including: H.R. 6157, the Defense and Labor, HHS, Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 respecting FY 2019 federal appropriations for NIH, NCI, and CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act, and the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the State/Foreign Operations Appropriations Act; issues related to medical isotopes with respect to the Energy and Water Development Appropriations Act;; and issues relating to global health funding for HPV vaccination and cervical cancer screening and treatment.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Energy - Dept of, Veterans Affairs - Dept of (VA), Veterans Affairs - Dept of (VA), Veterans Affairs - Dept of (VA), White House Office, U.S. Agency for International Development (USAID), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Rachel |
Marcus |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on establishment of Medicaid payment for patient navigation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia |
Woods |
|
|
|
Denys |
Symonette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the FDA deeming regulation. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control as considered in House and Senate, FY18 and The FY19 Agriculture Appropriations legislation and CDC tobacco activities as considered in the Labor, Health and Human Services Appropriations legislation. Issues related to making Veterans Health Administration facilities smoke-free respecting H.R. 1662, H.R. 1848, and S. 2119. Issues regarding parity in taxation of tobacco products respecting S. 1837. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273. Issues regarding flavors in tobacco products including e-cigarettes and cigars respecting S.3319, the SAFE Kids Act, and development of similar legislation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Veterans Affairs - Dept of (VA), Health & Human Services - Dept of (HHS), U.S. Trade Representative (USTR), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Denys |
Symonette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988, S. 2123 and H.R. 5771, The Charitable Giving Tax Deduction Act. H.R. 1337, Legacy IRA Act respecting charitable giving and life income planning, and H.R. 6760, the Protecting Family and Small Business Tax Cuts Act of 2018 respecting the medical expense deduction
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Denys |
Symonette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues relating to access to care, health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; H.R. 4122 & S. 2006, the Breast Density & Mammography Reporting Act; H.R.820 & S.292, the Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, issues related to reform of laboratory and diagnostic tests and the development of a new discussion draft for the Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. The proposed Medical Records Fairness Act (no number yet). Issues regarding the Affordable Care Act premium tax credits and catastrophic plans, HR 6311. Issues regarding protections for people with pre-existing conditions, including S. 3388, HR 6898, and H. Res. 1066. Resolutions to disapprove the short-term rule, H.J. Res 140 and S. J. Res. 63. Advocacy against including the Association Health Plan provision of the House Farm bill in the conference report, H.R. 2 and s. 3042 (section 6004 of the House-passed version of the legislation). Issues involving patient navigation, including the Patient Navigation Assistance Act, HR 6808. H.R. 6, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, respecting Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, and protecting communities. Draft legislation on patient access to medical records. Draft legislation on FDA regulation of laboratory tests. H.R. 4897 & S. 2358 Women and Lung Cancer Research and Preventive Services Act of 2018. Issues related to caregiving, including H.R. 3759/S. 1028, the RAISE Family Caregivers Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), U.S. Agency for International Development (USAID), Environmental Protection Agency (EPA), White House Office, Food & Drug Administration (FDA), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Caroline |
Powers |
|
|
|
Gregg |
Haifley |
|
|
|
Keysha |
Brooks-Coley |
|
|
|
Rosalie |
Abbott |
|
|
|
Emily |
Myatt |
|
|
|
Matt |
Phelan |
|
|
|
Stephanie |
Krenrich |
|
|
|
Phylicia |
Woods |
|
|
|
Denys |
Symonette |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |